Cargando…

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi‐centre 48‐week efficacy and safety study in Thailand

INTRODUCTION: Efavirenz (EFV) is commonly used for first‐line antiretroviral therapy in children and adolescents with HIV, but is associated with neuropsychiatric and metabolic side effects. Rilpivirine (RPV) is better tolerated, and switching from EFV to RPV in virologically suppressed adults has b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phongsamart, Wanatpreeya, Jantarabenjakul, Watsamon, Chantaratin, Sasitorn, Anugulruengkitt, Suvaporn, Suntarattiwong, Piyarat, Sirikutt, Pakpen, Kosalaraksa, Pope, Maleesatharn, Alan, Chokephaibulkit, Kulkanya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743364/ https://www.ncbi.nlm.nih.gov/pubmed/35001501 http://dx.doi.org/10.1002/jia2.25862

Ejemplares similares

Depression and Anxiety in Youth and Young Adults Living with HIV: Frequency and Associated Factors in Thai Setting
por: Chantaratin, Sasitorn, et al.
Publicado: (2022)

Streptococcus pneumoniae Causing Invasive Diseases in Children and Adults in Central Thailand, 2012–2016
por: Phongsamart, Wanatpreeya, et al.
Publicado: (2022)

Prevention of Emerging Infections in Children
por: Puthanakit, Thanyawee, et al.
Publicado: (2022)

The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
por: Chantasrisawad, Napaporn, et al.
Publicado: (2023)

HIV seronegativity in children, adolescents and young adults living with perinatally acquired HIV: A cross‐sectional study in Thailand
por: Wirotpaisankul, Praew, et al.
Publicado: (2020)

High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting
por: Puthanakit, Thanyawee, et al.
Publicado: (2012)

Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors
por: Santiprabhob, Jeerunda, et al.
Publicado: (2017)

The Outcomes of Transition from Pediatrics to Adult Care among Adolescents and Young Adults with HIV at a Tertiary Care Center in Bangkok
por: Rungmaitree, Supattra, et al.
Publicado: (2022)

Outcomes among Thai children with risk conditions hospitalized for pneumococcal disease (invasive or non-bacteraemic pneumonia): A multi-centre, observational study
por: Phongsamart, Wanatpreeya, et al.
Publicado: (2023)

Clinical outcomes of pediatric COVID-19 in a tertiary care center in Bangkok, Thailand
por: Anugulruengkitt, Suvaporn, et al.
Publicado: (2021)

Neurological complications associated with influenza in hospitalized children
por: Jantarabenjakul, Watsamon, et al.
Publicado: (2022)

Immunogenicity of a Two-Dose Human Papillomavirus Vaccine Schedule in HIV-Infected Adolescents with Immune Reconstitution
por: Rungmaitree, Supattra, et al.
Publicado: (2022)

Outcomes of Single-Dose Empirical Antibiotic Treatment in Children With Suspected Sepsis Implemented in the Emergency Department
por: Khanthathasiri, Suwimon, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
por: Chantasrisawad, Napaporn, et al.
Publicado: (2022)

Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand
por: Jarupan, Muttharat, et al.
Publicado: (2023)

Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine
por: Thisyakorn, Usa, et al.
Publicado: (2014)

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age
por: Chokephaibulkit, Kulkanya, et al.
Publicado: (2022)

Alcohol use, suicidality and virologic non‐suppression among young adults with perinatally acquired HIV in Thailand: a cross‐sectional study
por: Aurpibul, Linda, et al.
Publicado: (2023)

Temporal trend of drug-resistant tuberculosis among Thai children during 2006–2021
por: Jantarabenjakul, Watsamon, et al.
Publicado: (2022)

Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand
por: Sanchez, Leilani, et al.
Publicado: (2023)

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022)

Persistence of hepatitis B immune memory until 9–10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months
por: Kosalaraksa, Pope, et al.
Publicado: (2018)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

Comparing Interferon-Gamma Release Assays to Tuberculin Skin Test in Thai Children with Tuberculosis Exposure
por: Tieu, Hong-Van, et al.
Publicado: (2014)

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study
por: Teeranaipong, Phairote, et al.
Publicado: (2016)

Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans
por: Seneviratne, Herana Kamal, et al.
Publicado: (2020)

365. Neurocognitive Function Change after Switching from Efavirenz to Rilpivirine in HIV-Infected Adults: A Randomized Control Trial
por: Kaewpoowat, Quanhathai, et al.
Publicado: (2019)

The Happy Teen programme: a holistic outpatient clinic‐based approach to prepare HIV‐infected youth for the transition from paediatric to adult medical care services in Thailand
por: Lolekha, Rangsima, et al.
Publicado: (2017)

The Relationship Between Screen Time and Symptom Severity in Children with ADHD during COVID-19 Lockdown
por: Sriwaranun, Thanchanok, et al.
Publicado: (2023)

Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use
por: Maruapula, Dorcas, et al.
Publicado: (2023)

Outcomes in Older Versus Younger Patients Over 96 Weeks in HIV-1– Infected Patients Treated with Rilpivirine or Efavirenz in ECHO and THRIVE§
por: Ryan, Robert, et al.
Publicado: (2013)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
por: Shearer, Kate, et al.
Publicado: (2014)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

1184. A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
por: Bili, Adroniki, et al.
Publicado: (2021)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
por: Cutrell, Amy G., et al.
Publicado: (2021)

Immune Reconstitution Inflammatory Syndrome in Aids Patient After Successful Induction of Virological Suppression with Cabotegravir/Rilpivirine
por: Al-Handola, Rami, et al.
Publicado: (2023)

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART
por: Vera, Jaime H., et al.
Publicado: (2019)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Gynoid Fat Distribution and Adipocyte Trapping May Explain Virological Failure With Intramuscular Long-Acting Cabotegravir and Rilpivirine
por: de Malliard, Isabelle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4450v16d3d2brm92un6o5b1ipl